doi: 10.1016/j.neuroimage.2024.120632, 22 HupfeldK
doi: 10.3389/fphys.2025.1715513 Received 29 September 2025 Revised 05 November 2025 Accepted 06 November 2025 Published 21 November 2025 Volume 16 - 2025 Edited by Daichi Sumi, ASICS Institute of Sport Science, Japan Reviewed by Selma Arzu Vardar, Trakya University, Trkiye Mateusz Mardya, University of Physical Education in Krakow, Poland Updates Copyright 2025 Grau, Bruns, Stcher, John, Munk, Siebers, Siebers, Bloch and Bizjak
Additionally, lixisenatide was tested in a large cardiovascular safety trial ( ELIXA , in post-heart-attack diabetic patients) and was found cardiovascularly neutral it neither increased nor decreased CV events versus placebo ( [128] )
This effect proved stronger than common treatments for intracranial hypertension like acetazolamide or topiramate
You may encounter them in mixed-gauge packs or when specific syringe options are limited
K.SuwannaN.MangiardiM.et al (2013)